35 related articles for article (PubMed ID: 8832011)
1. Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation.
Cutler C; Stevenson K; Kim HT; Richardson P; Ho VT; Linden E; Revta C; Ebert R; Warren D; Choi S; Koreth J; Armand P; Alyea E; Carter S; Horowitz M; Antin JH; Soiffer R
Blood; 2008 Dec; 112(12):4425-31. PubMed ID: 18776081
[TBL] [Abstract][Full Text] [Related]
2. Incidence and risk factors of early onset VOD/SOS differ in younger vs older adults after stem cell transplantation.
Marcoux C; Saliba RM; Wallis W; Khazal S; Ragoonanan D; Rondon G; Tewari P; Popat U; Oran B; Olson A; Bashir Q; Qazilbash M; Alousi A; Hosing C; Nieto Y; Alatrash G; Marin D; Rezvani K; Khouri I; Srour S; Champlin R; Shpall E; Kebriaei P
Blood Adv; 2024 Mar; 8(5):1128-1136. PubMed ID: 38266155
[TBL] [Abstract][Full Text] [Related]
3. High exposures to bioactivated cyclophosphamide are related to the occurrence of veno-occlusive disease of the liver following high-dose chemotherapy.
de Jonge ME; Huitema AD; Beijnen JH; Rodenhuis S
Br J Cancer; 2006 May; 94(9):1226-30. PubMed ID: 16622453
[TBL] [Abstract][Full Text] [Related]
4. Constructing training set using distance between learnt graphical models of time series data on patient physiology, to predict disease scores.
Chakrabarty D; Wang K; Roy G; Bhojgaria A; Zhang C; Pavlu J; Chakrabartty J
PLoS One; 2023; 18(10):e0292404. PubMed ID: 37856497
[TBL] [Abstract][Full Text] [Related]
5. Clarifying busulfan metabolism and drug interactions to support new therapeutic drug monitoring strategies: a comprehensive review.
Myers AL; Kawedia JD; Champlin RE; Kramer MA; Nieto Y; Ghose R; Andersson BS
Expert Opin Drug Metab Toxicol; 2017 Sep; 13(9):901-923. PubMed ID: 28766962
[TBL] [Abstract][Full Text] [Related]
6. Experience from a single paediatric transplant centre with identification of some protective and risk factors concerning the development of hepatic veno-occlusive disease in children after allogeneic hematopoietic stem cell transplant.
Maximova N; Ferrara G; Minute M; Pizzol A; Kiren V; Montico M; Gregori M; Tamaro P
Int J Hematol; 2014 Jun; 99(6):766-72. PubMed ID: 24715523
[TBL] [Abstract][Full Text] [Related]
7. Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome.
Coppell JA; Richardson PG; Soiffer R; Martin PL; Kernan NA; Chen A; Guinan E; Vogelsang G; Krishnan A; Giralt S; Revta C; Carreau NA; Iacobelli M; Carreras E; Ruutu T; Barbui T; Antin JH; Niederwieser D
Biol Blood Marrow Transplant; 2010 Feb; 16(2):157-68. PubMed ID: 19766729
[TBL] [Abstract][Full Text] [Related]
8. Ursodiol to prevent hepatic venoocclusive disease.
Comcowich SA; Spitzer TR; Tsunoda SM
Ann Pharmacother; 1997 Oct; 31(10):1249-52. PubMed ID: 9337452
[TBL] [Abstract][Full Text] [Related]
9. Regimen-related acute toxicities: pathophysiology, risk factors, clinical evaluation and preventive strategies.
Klingemann HG; Shepherd JD; Reece DE; Barnett MJ; Nantel SH; Sutherland HJ; Spinelli JJ; Phillips GL
Bone Marrow Transplant; 1994; 14 Suppl 4():S14-8. PubMed ID: 7728119
[No Abstract] [Full Text] [Related]
10. Hepatic dysfunction following busulfan and cyclophosphamide myeloablation: a retrospective, multicenter analysis.
Styler MJ; Crilley P; Biggs J; Moul J; Copelan E; Topolsky D; Avalos B; Penza S; Sabol P; Downs K; Szer J; Brodsky I; Marks DI
Bone Marrow Transplant; 1996 Jul; 18(1):171-6. PubMed ID: 8832011
[TBL] [Abstract][Full Text] [Related]
11. Hepatic veno-occlusive disease post-bone marrow transplantation in children conditioned with busulfan and cyclophosphamide: incidence, risk factors, and clinical outcome.
Ozkaynak MF; Weinberg K; Kohn D; Sender L; Parkman R; Lenarsky C
Bone Marrow Transplant; 1991 Jun; 7(6):467-74. PubMed ID: 1908340
[TBL] [Abstract][Full Text] [Related]
12. Decreased incidence of hepatic veno-occlusive disease and fewer hemostatic derangements associated with intravenous busulfan vs oral busulfan in adults conditioned with busulfan + cyclophosphamide for allogeneic bone marrow transplantation.
Lee JH; Choi SJ; Lee JH; Kim SE; Park CJ; Chi HS; Lee MS; Lee JS; Kim WK; Lee KH
Ann Hematol; 2005 May; 84(5):321-30. PubMed ID: 15580502
[TBL] [Abstract][Full Text] [Related]
13. Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens.
Bleyzac N; Souillet G; Magron P; Janoly A; Martin P; Bertrand Y; Galambrun C; Dai Q; Maire P; Jelliffe RW; Aulagner G
Bone Marrow Transplant; 2001 Oct; 28(8):743-51. PubMed ID: 11781625
[TBL] [Abstract][Full Text] [Related]
14. Risk-adjusted monitoring of veno-occlusive disease following Bayesian individualization of busulfan dosage for bone marrow transplantation in paediatrics.
Brice K; Valerie B; Claire G; Valerie M; Yves B; Gilles A; Nathalie B
Pharmacoepidemiol Drug Saf; 2008 Feb; 17(2):135-43. PubMed ID: 17952879
[TBL] [Abstract][Full Text] [Related]
15. Antithrombin-III for the treatment of chemotherapy-induced organ dysfunction following bone marrow transplantation.
Morris JD; Harris RE; Hashmi R; Sambrano JE; Gruppo RA; Becker AT; Morris CL
Bone Marrow Transplant; 1997 Nov; 20(10):871-8. PubMed ID: 9404929
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
